Resumo

OROZCO, María Celeste et al. Validation of RAPID3 questionnaire in ESPAXIA Argentina cohort of patients with axial spondyloarthritis. Rev. argent. reumatolg. [online]. 2016, vol.27, n.4, pp.11-16. ISSN 0327-4411.

Introduction: RAPID3 (Routine Assessment of Patient Index Data 3) is a simple, quick and simple calculation questionnaire that showed good performance in patients with rheumatoid arthritis, being able to reflect the state of disease and quality of life in these patients. Objective: To validate the RAPID3 questionnaire in a cohort of patients with axial spondyloarthritis (axSpa) and assess its association with other measures of the disease. Materials and methods: We included consecutive patients ≥18 years of age diagnosed with axSpa (according to modified NY criteria 1987 and/or ASAS 2009). All patients completed the RAPID3, ASQoL, BASDAI and BASFI questionnaires. The overall assessment of the disease both by the patient and the doctor was determined by visual analog scale (VAS). Physical examination was performed with joint count (44) and evaluation of enthesis (MASES). Blood samples for determination of HLA-B27 and ERS were obtained. ASDAS-ERS and SASDAS-ERS were calculated. X-rays were evaluated by BASRI by a blinded reader (CCI=>0.92). The translated and validated in Argentina RAPID3 version was calculated. Time to complete the questionnaire by the patient and time to calculate by the doctor were determined. Results: 51 patients were included, 39 were male (76.5%), median age 42 years (IQR 33-51) and median disease duration of 20 years (IQR 10.3-27.6). 90.5% had HLA-B27. Median RAPID3 was 9 (IQR 3-12.8), BASDAI 3.35 (IQR 1.6-6), BASFI 3.4 (IQR 1.1-5.6), ASQoL 5 (IQR 1-9), SASDAS-ESR 15.9 (IQR 8-22.6), MASES 1 (IQR 0-3) and BASRI 4.5 (IQR 0-11). The questionnaire had excellent reproducibility (ICC = 0.97). The median time to complete the RAPID3 was 2 minutes (IQR 0.91 to 3), and to calculate 10 seconds (IQR 6-15). RAPID3 had very good correlation with SASDAS ESR (r:0.87), BASDAI (r:0.89), BASFI (r=0.8) and ASQoL (r=0.83) and good with MASES (r:0.58). In multiple linear regression, using total RAPID score as dependent variable and adjusting for age, sex and disease duration, a significant association was observed with BASFI (β coeff 0.25, p=0.008), ASQoL (β coeff: 0.22, p=0.02), and mainly with SASDAS ERS (β coeff: 0.42, p=0.001) and BASDAI (0.55, p=0.0001). Conclusion: RAPID3 is a valid, reliable and reproducible questionnaire to be used in axSpa. It is simple to complete by the patient and to evaluate by the rheumatologist.

Palavras-chave : RAPID3; ESPAXIA; Argentina; axial spondyloarthritis.